Experienced operational leader across medical research and deep tech appointed to support sustainable growth as part of Qureight’s strategy to scale company operations

Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials, today announced the appointment of Rebecca Simmons as Chief Operating Officer.

Rebecca will be responsible for scaling the Company’s global business operations and leading sustainable growth initiatives, as Qureight drives increased adoption and integration of its AI-powered CT imaging biomarkers and clinical data management platform in clinical trials for lung and heart diseases. She will play an instrumental role in driving operational excellence and supporting Qureight’s scientific and technical functions.

With over 20 years of operational leadership experience, Rebecca was previously COO at quantum computing company Riverlane, where she successfully built and scaled the company’s operations to support rapid growth, from ten to 100 employees over five years. She also played a key role in closing Series A, B and C funding rounds, helping to raise over £100M in venture capital, and supported business development activities, including raising over £20M in government grants and contracts. Prior to Riverlane, Rebecca was deputy director and co-founder of THIS Institute (The Healthcare Improvement Studies Institute), where she developed strategic partnerships with key stakeholders in the NHS. She has also held senior advisory roles at the Danish Diabetes and Endocrine Academy. Rebecca was awarded a PhD in Epidemiology from the University of Cambridge and holds an MBA from The Open University, an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, and BA in Human Sciences from the University of Oxford.

Muhunthan Thillai, MD, Co-founder and CEO, Qureight, commented: “Rebecca’s experience, expertise and people-centric leadership approach will be instrumental in supporting the team as we scale the company, accelerating our mission to advance the understanding of lung and heart disease. Her blend of rigorous academic training with commercial acumen made Rebecca the natural choice to lead this next chapter of growth for Qureight. Welcome to the team, Rebecca.”

Rebecca Simmons, PhD, Chief Operating Officer, Qureight, added: “Qureight’s pioneering AI-powered CT imaging biomarkers and data management platform is enabling real insights to be drawn from complex and diverse health data, to ultimately deliver real impact for patients. The team is already incredible, with an expert team of clinicians, scientists and machine learning engineers. I’m delighted to join the company and am looking forward to an exciting year!”